Rodman & Renshaw Initiates Coverage of Arena Pharmaceuticals (ARNA) with a Market Outperform
More News related to ARNA
- Trading Radar for 11/09: Dish Network (DISH), Rockwell (ROK), Priceline.com (PCLN), MBIA (MBI), Ticketmaster (TKTM) Report
- Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, November 10, 2009
- New Data From Arena Pharmaceuticals' Pivotal BLOSSOM Trial of Lorcaserin Demonstrate Improvements in Patients' Body Composition, Cardiovascular Risk Factors and Quality of Life
- Arena Pharma (ARNA) Reports Pivotal BLOOM Phase III data
- Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with
Rodman & Renshaw initiates coverage of Arena Pharmaceuticals (Nasdaq: ARNA) with a Market
Outperform rating Price target $9.
Rodman analyst says, "We view the company's obesity drug, lorcaserin, as promising relative to marketed and development-stage obesity drugs."
To see more analyst ratings on ARNA Click Here.
Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.
Related Categories
New CoverageStocks Mentioned
-0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
